Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Lancet Reg Health Eur
; 28: 100613, 2023 May.
Article
en En
| MEDLINE
| ID: mdl-37131861
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Año:
2023
Tipo del documento:
Article